You are here: Industry Insights > Bavarian Nordic

News List

Bavarian Nordic Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine americanpharmaceuticalreview
August 10, 2021
Bavarian Nordic A/S reported initial results from the first-in-human trial of ABNCoV2, led by the PREVENT-nCoV consortium.
Bavarian Nordic licences Covid-19 vaccine from AdaptVac pharmaceutical-technology
July 23, 2020
Bavarian Nordic has signed a final agreement with AdaptVac to licence a capsid virus-like particle (cVLP) based SARS-CoV-2 subunit vaccine.
Valneva, Bavarian Nordic Announce Marketing and Distribution Partnership americanpharmaceuticalreview
June 30, 2020
Valneva and Bavarian Nordic have signed a binding term sheet to establish a partnership for the marketing and distribution of their commercial products.
Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen contractpharma
June 19, 2020
Deal valued at $13.9 million; manufacturing to begin this year.
Bavarian Nordic Announces FDA Acceptance of BLA for MVA-BN Smallpox Vaccine americanpharmaceuticalreview
December 27, 2018
Bavarian Nordic announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for the liquid-frozen version of the MVA-BN for active immunization against smallpox in.......
Bavarian Nordic and Janssen to develop vaccines against HIV-1 and hepatitis B August 01, 2017
Danish biotechnology company Bavarian Nordic has entered an additional worldwide exclusive licence and collaboration agreement with Janssen Pharmaceuticals for the development of vaccine regimens against HIV-1 and hepatitis B.